Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Long Term Outcome of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients (pts) from the French Spirit Study Comparing Imatinib (IM) 400 Mg to Higher Dose Imatinib or Combination with Peg-interferonα2a (PegIFN) or Cytarabine (Ara-C) : A Trial of the FI LMC (France intergroupe de la leucemie myéloïde chronique)

Francois Guilhot, Francoise Rigal-Huguet, MD, Joelle Guilhot, PhD, Agnès Guerci-Bresler, MD, Franck E. Nicolini, MD PhD, Frédéric Maloisel, Delphine Rea, MD PhD, Valerie Coiteux, MD, Martine Gardembas, MD, Anne Vekhoff, MD, Eric Jourdan, MD PhD, Laurence Legros, MD PhD, Martine Escoffre-Barbe, MD, Philippe Rousselot, MD, Claude Preudhomme, MD PhD, Francois-Xavier Mahon, MD PhD

Blood (2014) 124 (21): 1793.

https://doi.org/10.1182/blood.V124.21.1793.1793

Published: 2014

Journal Articles

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

Philippe Rousselot, MD, PhD, Joelle Guilhot, PhD, Claude Preudhomme, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Franck E. Nicolini, MD, PhD, Francoise Rigal-Huget, MD, Hyacinthe Johnson-Ansah, MD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, Eric Jourdan, MD, Laurence Legros, MD, PhD, Francois Guilhot

Blood (2012) 120 (21): 168.

https://doi.org/10.1182/blood.V120.21.168.168

Published: 2012

Journal Articles

ABCG2 Polymorphism Is Associated with Lower Major Molecular Response Rates in CML Patients Treated with 400 Mg Imatinib but Not in Patients Treated with 600 Mg Imatinib.

Marc Delord, Philippe Rousselot, MD, PhD, Jean-Michel Cayuela, Pascale Loiseau, Odile Maarek, Francois Sigaux, MD, Joelle Guilhot, PhD, Claude Preudhomme, Francois Guilhot, Fabien Calvo, Heriberto Bruzzoni-Giovanelli

Blood (2012) 120 (21): 2465.

https://doi.org/10.1182/blood.V120.21.2465.2465

Published: 2012

Journal Articles

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Hyacinthe Johnson-Ansah, MD, Joelle Guilhot, Philippe Rousselot, MD, PhD, Rea Delphine, MD, PhD, Francoise Rigal-Huguet, MD, Franck E. Nicolini, MD, PhD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, PhD, Michele Schoenwald, MD, Eric Jourdan, Laurence Legros, Valérie Coiteux, MD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, Francois Guilhot

Blood (2011) 118 (21): 456.

https://doi.org/10.1182/blood.V118.21.456.456

Published: 2011

Journal Articles

Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Claude Preudhomme, MD, PhD, Catherine Roche-Lestienne, MD/PHD, Antoine Crinquette, MD, Christophe Roumier, MD/PHD, Virginie Eclache, MD, Joëlle Guilhot, MD, Francois Guilhot, MD/PHD, François-Xavier Mahon, MD/PHD

Blood (2006) 108 (11): 2150.

https://doi.org/10.1182/blood.V108.11.2150.2150

Published: 2006

Journal Articles

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Catherine Roche-Lestienne, MD, PhD, François-Xavier Mahon, MD/PHD, Antoine Crinquette, MD, Joëlle Guilhot, PhD, Francois Guilhot, MD/PHD, Claude Preudhomme, MD/PHD

Blood (2006) 108 (11): 2151.

https://doi.org/10.1182/blood.V108.11.2151.2151

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

ABCG2 Polymorphism Is Associated with Lower Major Molecular Response Rates in CML Patients Treated with 400 Mg Imatinib but Not in Patients Treated with 600 Mg Imatinib.

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Email alerts

ASH Publications

American Society of Hematology

Update search

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

ABCG2 Polymorphism Is Associated with Lower Major Molecular Response Rates in CML Patients Treated with 400 Mg Imatinib but Not in Patients Treated with 600 Mg Imatinib.

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only